98 completed, 20 unknown, 9 withdrawn, 3 terminated. 48 Phase 2, 45 Phase 3, 17 Phase 1, 11 Phase 4, 7 Not applicable.
Follow daclatasvir: new trials by email Literature Review of daclatasvir trials Research Report on daclatasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily - Heptatitis C | Not applicable | Completed | Indus Hospital and Health Network | 192 | 2024-01-10 | 2026-07-14 |
| Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia Sofosbuvir/Daclatasvir - HCV Infection | Not applicable | Active not recruiting | ANRS, Emerging Infectious Diseases | 21000 | 2023-08-07 | 2025-12-04 |
| Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults AV-COVID-19 - COVID-19 | Phase 1 / Phase 2 | Withdrawn | Aivita Biomedical, Inc. | 2023-01-01 | 2023-05-03 | |
| Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera sofosbuvir and daclatasvir - Hepatitis C, Chronic | Early Phase 1 | Unknown | Assiut University | 40 | 2022-10-01 | 2022-07-26 |
| Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets - HCV | Phase 3 | Unknown | Ain Shams University | 30 | 2022-06-05 | 2023-05-11 |
| Hepatitis C Treatment Study in Myanmar Sofosbuvir 400 mg - Hepatitis C | Withdrawn | Myanmar Oxford Clinical Research Unit | 2022-01-01 | 2021-12-17 | ||
| Antiviral Agents Against COVID-19 Infection Atazanavir, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg - COVID-19 | Phase 2 / Phase 3 | Completed | Hospital do Coracao | 256 | 2021-02-15 | 2024-03-22 |
| Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) Sofosbuvir 400 MG plus Daclatasvir 200mg - COVID-19 | Phase 3 | Unknown | Mansoura University | 50 | 2020-12-28 | 2021-02-24 |
| COVID-19 Prophylaxis South Africa (COVER HCW) Nitazoxanide, Sofosbuvir/Daclatasvir - Covid19, SARS-CoV Infection | Phase 2 | Completed | University of Witwatersrand, South Africa | 1950 | 2020-12-08 | 2022-06-07 |
| Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt Sofosbuvir 400 MG/ Daclatasvir 60mg - Covid19 | Phase 4 | Completed | Alexandria University | 54 | 2020-11-01 | 2021-02-26 |
| Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Paracetamol, Artesunate-amodiaquine, Pyronaridine-artesunate - COVID-19 | Phase 2 | Completed | Shin Poong Pharmaceutical Co. Ltd. | 192 | 2020-09-03 | 2025-07-28 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients Sofosbuvir, Daclatasvir - Covid19 | Phase 2 / Phase 3 | Unknown | Tanta University | 100 | 2020-07-01 | 2020-12-03 |
| Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | Cairo University | 100 | 2020-07-01 | 2020-06-25 |
| Metabolic Changes in Chronic HCV Patients Receiving DAAS sofosbuvir plus daclatasvir, Sofosbuvir plus Ledipasvir - Chronic Hepatitis C | Unknown | Ain Shams University | 100 | 2019-10-01 | 2020-01-02 | |
| Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c | Phase 3 | Unknown | Assiut University | 50 | 2019-09-01 | 2019-09-12 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 440 | 2019-03-29 | 2019-08-28 |
| Safety of Sofosbuvir in People With Advanced Kidney Failure Sofosbuvir, Daclatasvir 60 mg - Kidney Failure, Chronic, Hepatitis C | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 30 | 2019-03-15 | 2021-04-06 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 |
Showing 20 of 133. Sign in to see all of them.
Hepatitis C (74) · Hepatitis C, Chronic (33) · COVID-19 (8) · Fibrosis (5) · Hepatitis, Chronic (4) · Kidney Failure, Chronic (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis (2) · Renal Insufficiency (2) · Bronchiolitis Obliterans Syndrome (1) · Camurati-Engelmann Syndrome (1) · Carcinoma, Hepatocellular (1) · Coinfection (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1)
Bristol-Myers Squibb (52) · ANRS, Emerging Infectious Diseases (5) · Humanity and Health Research Centre (5) · Ain Shams University (4) · Assiut University (4) · Tehran University of Medical Sciences (4) · Genuine Research Center, Egypt (3) · Tanta University (3) · Janssen R&D Ireland (2) · Janssen Research & Development, LLC (2) · Nanjing Sanhome Pharmaceutical, Co., Ltd. (2) · Radboud University Medical Center (2) · Third Affiliated Hospital, Sun Yat-Sen University (2) · Valme University Hospital (2) · Zagazig University (2)
United States (41) · France (29) · Egypt (21) · Spain (18) · Australia (16) · Germany (16) · Canada (15) · Italy (15) · Puerto Rico (12) · Argentina (11) · Russia (11) · United Kingdom (11) · China (10) · Japan (10) · South Korea (10)
Ahmed Elshafeey, Ph.D. Pharma (3) · David Burger, PharmD, PhD (2) · George KK Lau, MD (2) · George Lau, MD (2) · Ahmed Cordie, lecturer (1) · Aisha El Sharkawy, MD (1) · Alla Andreeva, PhD (1) · Amit Goel, DM (1) · Amr Maged (1)
PMID 26683763, PMID 24428467, PMID 30853642, PMID 37671831, PMID 11413125, PMID 12450640, PMID 12618532, PMID 12823087, PMID 15560058, PMID 15637534, PMID 17695343, PMID 19897823, PMID 21837752, PMID 22256805, PMID 22714001, PMID 23059806, PMID 23178977, PMID 23183526, PMID 23300053, PMID 23504694, PMID 23607593, PMID 23607594, PMID 24184132, PMID 24468783, PMID 24604476, PMID 25078304, PMID 25080450, PMID 25311593, PMID 25614962, PMID 25654812, PMID 25703086, PMID 25942724, PMID 25977266, PMID 26083155, PMID 26196502, PMID 26223768, PMID 26313445, PMID 26453968, PMID 26473667, PMID 27009831, PMID 27025835, PMID 27188960, PMID 27287851, PMID 27327078, PMID 27415157, PMID 27605539, PMID 27798211, PMID 27845298, PMID 27878906, PMID 27882706
2014 (3), 2015 (3), 2017 (1), 2019 (1), R01DA026727 (1)